Filter By Category
Archives
Share on -
ACTINIUM (225Ac) LINTUZUMAB SATETRAXETAN
Generic Name: ACTINIUM (225Ac) LINTUZUMAB SATETRAXETAN
ABSTRACT -
Actinium (225Ac) Lintuzumab Satetraxetan is an investigational antibody-radioconjugate consisting of lintuzumab (anti-CD33 humanized monoclonal antibody, HuM195) radiolabeled with actinium-225 via a satetraxetan (DOTA-derivative) chelator. It targets CD33-expressing leukemic cells for targeted alpha therapy. It is being investigated for acute myeloid leukemia (AML) and other myeloid malignancies.
DOSAGE -
Actinium (225Ac) Lintuzumab Satetraxetan is administered as an intravenous infusion in clinical trial settings. Dosage is patient-specific and determined by study protocol, body surface area, and clinical condition. Administered only in specialized hematology-oncology centers with radiation safety infrastructure.
SIDE EFFECTS –
Reported or potential side effects may include:
- Bone marrow suppression (myelosuppression)
- Thrombocytopenia
- Anemia
- Neutropenia
- Fatigue
- Nausea
- Vomiting
- Fever
- Infusion reactions
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Hypersensitivity to murine or humanized antibody components
- Infusion-related reactions
- Anaphylaxis (rare)
- Angioedema
- Urticaria
DRUG INTERACTIONS–
- Other myelosuppressive chemotherapy agents
- Granulocyte colony-stimulating factors (G-CSF)
- Immunosuppressants
- Nephrotoxic agents
PREAUTIONS–
- Other myelosuppressive chemotherapy agents
- Granulocyte colony-stimulating factors (G-CSF)
- Immunosuppressants
- Nephrotoxic agents
WARNINGS –
- Risk of severe and prolonged myelosuppression.
- Radiation hazard to patient and close contacts.
- Not approved for general clinical use.
- Administered only under specialist hematology-oncology supervision.
- Keep out of reach of children.
Share on -
. Developed by